Heterogeneous reactivity of ICAM-1 on alveolar macrophages (AMs) in patients with non-small cell lung cancer (NSCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 256s Year: 2003
Bevacizumab (Avastin®) aerosol therapy (AT) inhibits primary and metastatic tumor growth in a murine model with human non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Treatment of lung cancer Year: 2012
Expression of vascular endothelial growth factor (VEGF) and association with lymphangiogenesis in non small cell (NSCLC) and small cell lung carcinomas (SCLC) Source: Eur Respir J 2006; 28: Suppl. 50, 386s Year: 2006
Epidermal growth factor receptor (EGFR) expression in non-small cell lung carcinoma (NSCLC) and survival Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015
Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer Source: Eur Respir J 2007; 30: 627-632 Year: 2007
TNFα as a prognostic factor in surgically treated non-small cell lung carcinomas Source: Annual Congress 2005 - Management of lung cancer: clinical problems Year: 2005
The prognostic value of serum epidermal growth factor receptor (EGFR) levels in patients with non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 674s Year: 2004
Gene expression profiles in non-small cell lung cancer (NSCLC) and lung tissue in smokers and non-smokers Source: Annual Congress 2009 - Hot topics in molecular pathology and functional genomics of lung cancer Year: 2009
Serum level of GFBP-1 and IGFBP-6 in patients with non-small cell lung cancer (NSCLC) during chemotherapy Source: Annual Congress 2009 - Biological and clinical markers in lung cancer Year: 2009
Pre-operative levels of serum vascular endothelial growth factor A (VEGF-A), C (VEGF-C) and D (VEGF-D) in non-small cell lung cancer (NSCLC). Preliminary report Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008
Role of EBUS-TBNA in the study of PD-L1 expression in patients with non-small cell lung cancer (NSCLC) Source: Virtual Congress 2020 – Endobronchial ultrasound: from rookie to pro Year: 2020
Investigation of survivin gene polymorphism in non-small cell lung cancer patients (NSCLC) Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012
Role of chemokines in resectable non-small cell lung cancer (NSCLC) Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019
Espression of vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1-Flt1, VEGF-R2-Flk1) in non small cell (NSCLC) and small cell lung carcinomas (SCLC). Correlation with clinical outcome Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008
Cytotoxicity and apotosis of alveolar lymphocytes (AL) in early clinical stage (I-IIa) of non-small cell lung cancer (NSCLC) Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores Year: 2018
Impact of PD-L1 expression levels on the response to pembrolizumab in metastatic non-small cell lung cancer> Source: Virtual Congress 2021 – Screening, diagnosis, management and prognosis of lung cancer Year: 2021
Risk factor for survival in never-smokers non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Thoracic malignancies: interesting case studies and series Year: 2010
Polymorphisms in the interleukin-10 gene promoter are associated with susceptibility to non-small cell lung cancer (NSCLC) Source: Eur Respir J 2005; 26: Suppl. 49, 458s Year: 2005
Vascular endothelial growth factor in sera of patients with non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 330s Year: 2005
The influence of secondary infectious process on non-small cell lung cancer (NSCLC) patients survival Source: Eur Respir J 2007; 30: Suppl. 51, 280s Year: 2007